Efficacy of SARS-CoV-2 vaccines and the dose–response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled …
ZR Yang, YW Jiang, FX Li, D Liu, TF Lin… - The Lancet …, 2023 - thelancet.com
Background The efficacy of SARS-CoV-2 vaccines in preventing severe COVID-19 illness
and death is uncertain due to the rarity of data in individual trials. How well the antibody …
and death is uncertain due to the rarity of data in individual trials. How well the antibody …
COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
The world is presently in crisis facing an outbreak of a health‐threatening microorganism
known as COVID‐19, responsible for causing uncommon viral pneumonia in humans. The …
known as COVID‐19, responsible for causing uncommon viral pneumonia in humans. The …
COVID-19 vaccines: where did we stand at the end of 2023?
K Lundstrom - Viruses, 2024 - mdpi.com
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
Autoimmune response after SARS-CoV-2 infection and SARS-CoV-2 vaccines
A Hromić-Jahjefendić, K Lundstrom, M Adilović… - Autoimmunity …, 2024 - Elsevier
The complicated relationships between autoimmunity, COVID-19, and COVID-19
vaccinations are described, giving insight into their intricacies. Antinuclear antibodies (ANA) …
vaccinations are described, giving insight into their intricacies. Antinuclear antibodies (ANA) …
Efficacy of approved versus unapproved vaccines for severe acute respiratory syndrome coronavirus 2 infection in randomized blinded clinical trials
A Perez Navarro, V Pilkington… - Open Forum …, 2022 - academic.oup.com
Background Five severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines
are approved in North America and/or Europe: Pfizer/BioNTech, Moderna, Janssen, Oxford …
are approved in North America and/or Europe: Pfizer/BioNTech, Moderna, Janssen, Oxford …
COVID-19 Vaccines: Where Did We Stand at the End of 2023? Viruses 2024, 16, 203
K Lundstrom - 2024 - europepmc.org
Vaccine development against SARS-CoV-2 has been highly successful in slowing down the
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
COVID-19 pandemic. A wide spectrum of approaches including vaccines based on whole …
[TRÍCH DẪN][C] Immunobiology and immunotherapy of COVID-19
K Lundstrom - 2025 - Elsevier